Related Experiment Videos
Rizatriptan in the treatment of migraine
C G Dahlof1, A M Rapoport, F D Sheftell
1Gothenburg Migraine Clinic, Sweden.
Clinical Therapeutics
|July 13, 2000
Summary
Rizatriptan effectively treats acute migraine in adults. Clinical trials show 10mg rizatriptan significantly relieves headache pain and associated symptoms, with generally mild side effects.
Area of Science:
- Neurology
- Pharmacology
Background:
- Rizatriptan is a selective 5-hydroxytriptamine1B/1D receptor agonist.
- Launched in 1998, it is used for acute migraine treatment in adults.
Purpose of the Study:
- To evaluate the efficacy and tolerability of oral rizatriptan doses (5mg and 10mg) for acute migraine treatment.
Main Methods:
- Analysis of data from 6 large clinical trials.
- Inclusion of patients aged 18+ diagnosed with migraine per International Headache Society criteria.
- Comparison of rizatriptan doses against placebo.
Main Results:
- Rizatriptan (5mg and 10mg) effectively relieves headache pain and associated migraine symptoms.
- The 10mg dose demonstrated higher efficacy than the 5mg dose.
- At 2 hours post-dosing, 77% of patients on 10mg rizatriptan experienced pain relief versus 37% on placebo.
Conclusions:
- Rizatriptan is an effective and well-tolerated acute treatment for migraine.
- Both 5mg and 10mg doses are safe, with most side effects being mild and transient.